Among cases identified by telephone survey, no significant increase in the incidence of lung cancer was reported during the three surveys. Despite recent reviews of the available data, no specific trends or epidemiologic relationships among risk factors or factors thought to be risk factors for either lung cancer development or mortality have been identified. However, some associations between lung cancer and other factors have been reported, and some have been shown to increase the risk of lung cancer. Thus, even if no clear picture emerges from all of the available data, the association of some risk factors with lung cancer is strong enough to justify a careful inquiry into the associations between those risk factors and lung cancer risk.
It is difficult to distinguish between COPD and lung cancer based solely on clinical characteristics, but clinical features such as a history of cigarette smoking, cough and shortness of breath on rising should prompt consideration of lung cancer.
Approximately 56,000 newly diagnosed lung cancers will be diagnosed in 2020. This is an average of 5.1 diagnoses per 100,000 population. This translates to an annual incidence of around 35 new lung cancer diagnoses per 100,000 persons (average of 5.1 diagnoses per 100,000 persons).
The only option for cure of lung cancer is the surgical removal with lymph node dissection of the primary tumor. Although radiotherapy, particularly in those with large tumors, provides a survival rate comparable to that found for resection, local control is incomplete, and this may be due to the high rate of local failures. Surgical resection is justified only as an adjunct to radiotherapy in the hope that the local control achieved by surgery will result in improved overall survival.
There are more people diagnosed with lung cancer during their 50s than in any other age group. Over the past decade, the prevalence of lung cancer has decreased in men after a large increase from the early 1980s, whereas it has increased in women. The most common forms of treatment include surgery, chemotherapy, hormonal, targeted, and/or targeted and hormonal therapy. Treatments are often provided in a multimodality treatment approach, using both surgery, chemotherapy, and/or targeted chemotherapy. In the United States, the most common form of the disease is non-small cell lung cancer, occurring in 20% of cases.
The word [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) is not a very well-known name which is associated with the lung tissue but it is a cancer of lung tissue.
The addition of cisplatin to a standard regimen of carboplatin + etoposide did not improve the control of disease, as assessed by tumour volume, or survival in this small study.
Although cisplatin is often used in combination with other medications, the addition of gemcitabine and cisplatin are not very effective by themselves. The addition of either cisplatin or gemcitabine did not significantly improve the effectiveness of cisplatin alone to treat first or second line patients with stage III non-small cell bronchial carcinoma.
The use of cisplatin is highly effective as salvage chemotherapy in patients with squamous cell cancer. The response rate is 20%. In this population of patients, the use of cisplatin reduces the number of subsequent hospitalizations by 50%, as well as suppressing the number of subsequent metastases.
The current data suggested that cisplatin was well tolerated and did not increase the risk of haematological toxicity or other adverse reactions associated with its use in patients with advanced NSCLC. Patients who required intensive care for their primary malignancy during chemotherapy were at a heightened risk of haematological disease.
Cisplatin (the standard chemotherapeutic agent for [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)) is most efficacious in lung cancers that have not infiltrated the peripheral region of the lung, as well. In those cases, the drug can be given as adjuvant therapy after a complete resection of the tumor has been accomplished. However, if the tumor has locally invaded the pleural cavity, then the addition of cisplatin, along with surgery, is not effective and does no good. When an infiltrating cancer is found in the pleural cavity, treatment with a combination of chemotherapy is not efficacious. Chemotherapy treatment should be avoided because its use implies the removal of a small amount of tissue in order to administer it.
The primary cause of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) appears to be tobacco-associated carcinogenesis, whereas asbestos, environmental tobacco smoke and some occupational dusts may also contribute to lung cancer. Lung cancer is one of the leading causes of cancer-related death and disability in Canada. For some lung cancers, lung cancer seems be not to be the primary cause of death or disability, but secondary causes such as lung cancer-associated cardiovascular disease, non-cancer lung disease, other cancers, and second malignancies. Further epidemiologic and molecular studies are warranted to explore the true etiology of lung cancer.